CORONAVIRUS/Taiwan-developed COVID drug trial shows positive clinical results
01/05/2022 09:09 PM
Taipei, Jan. 5 (CNA) Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
More in CORONAVIRUS
- Taiwan reports 23,394 new COVID-19 cases, 45 deathsTaiwan on Tuesday reported 23,394 new cases of COVID-19 and 45 deaths from the disease, according to the Central Epidemic Command Center (CECC).02/07/2023 02:22 PM
- Taiwan begins phasing out Pfizer-BNT as first vaccine shot for minorsTaiwan will stop offering the Pfizer-BioNTech COVID-19 vaccine as a first vaccine shot for children aged 6 months to 4 years and 12-17 years with immediate effect, the Central ...02/06/2023 05:26 PM
- Taiwan reports 16,640 new COVID-19 cases, 63 deathsTaiwan on Monday reported 16,640 new cases of COVID-19 and 63 deaths from the disease, according to the Central Epidemic Command Center (CECC).02/06/2023 02:31 PM
Latest
- Politics
DPP suspends membership of Tainan City Council speaker, deputy speaker
02/07/2023 07:40 PM - Politics
Envoy back in Taiwan to brief government on relations with Washington
02/07/2023 07:05 PM - Cross-Strait
Local councilors call for turning Kinmen into demilitarized zone
02/07/2023 06:41 PM - Society
Over 400 Taiwanese tourists in Turkey all safe from the earthquake
02/07/2023 06:15 PM - Society
Probe underway after Chiayi student killed, suspect commits suicide
02/07/2023 05:32 PM